Current address: Drug Innovation & Approval, Aventis Pharmaceuticals Corporation, 1041 Route 202–206, PO Box 6800, Bridgewater, NJ, U.S.A.
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2
Article first published online: 29 JAN 2009
2005 British Pharmacological Society
British Journal of Pharmacology
Volume 144, Issue 4, pages 538–550, February 2005
How to Cite
Esser, R., Berry, C., Du, Z., Dawson, J., Fox, A., Fujimoto, R. A., Haston, W., Kimble, E. F., Koehler, J., Peppard, J., Quadros, E., Quintavalla, J., Toscano, K., Urban, L., van Duzer, J., Zhang, X., Zhou, S. and Marshall, P. J. (2005), Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. British Journal of Pharmacology, 144: 538–550. doi: 10.1038/sj.bjp.0706078
- Issue published online: 29 JAN 2009
- Article first published online: 29 JAN 2009
- (Received June 17, 2004, Revised October 20, 2004, Accepted November 1, 2004)
- cyclooxygenase-2 selective inhibitor;
- 1This manuscript presents the preclinical profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor.
- 2Lumiracoxib inhibited purified COX-1 and COX-2 with Ki values of 3 and 0.06 μM, respectively. In cellular assays, lumiracoxib had an IC50 of 0.14 μM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 μM (HEK 293 cells transfected with human COX-1).
- 3In a human whole blood assay, IC50 values for lumiracoxib were 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515).
- 4Lumiracoxib was rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h.
- 5Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B2 (TxB2) generation with an ID50 of 33 mg kg−1, whereas COX-2-derived production of prostaglandin E2 (PGE2) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID50 value of 0.24 mg kg−1.
- 6Efficacy of lumiracoxib in rat models of hyperalgesia, oedema, pyresis and arthritis was dose-dependent and similar to diclofenac. However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg−1 orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).
- 7Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.
British Journal of Pharmacology (2005) 144, 538–550. doi:10.1038/sj.bjp.0706078